ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2080

Epidemiology and Outcomes of Emergency Department Visits in Systemic Lupus Erythematosus: Data from National Emergency Database Sample

Rashmi Dhital1, Monica Guma2, Brian Pedersen1, Ashbina Pokharel3 and Kenneth Kalunian4, 1UC San Diego, San Diego, CA, 2UCSD, La Jolla, CA, 3William Beaumont Hospital, Royal Oak, MI, 4University of California San Diego, La Jolla, CA

Meeting: ACR Convergence 2022

Keywords: Administrative Data, Comorbidity, Epidemiology, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2022

Title: SLE – Diagnosis, Manifestations, and Outcomes Poster III: Outcomes

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: Patients with autoimmune rheumatic diseases presenting to the emergency department (ED) often have multi-organ pathology. SLE patients may be particularly prone to ED visits due to disease complexity, flares, medication burden and non-adherence. Only a few studies have assessed ED use in SLE. We aim to characterize the ED visits in SLE patients using the largest all-payer ED database in the US, the national emergency database sample (NEDS).

Methods: Using the 2019 NEDS database, we compared the differences in baseline demographic characteristics, clinical comorbidities, and ED outcomes in SLE adults to those without SLE. NEDS contains ~ 20% sample from 989 hospital-owned US EDs. We identified SLE using ICD-10 code M32.xx. We used multivariable logistic regression to assess factors associated with inpatient admission from the ED. We also studied the top ten primary diagnoses among SLE and age and sex-matched controls without SLE, as well as among SLE ED visits admitted versus released from the ED. We used STATA v13 for analysis.

Results: Of 117,343,370 ED visits for adults ≥ 18 years in 2019, 414,769 had SLE. As expected, ED visits in SLE patients comprised of a higher proportion of women (91% vs 56%), non-Whites (55% vs 42%), and patients 31-50 years old (41% versus 31 %) than the non-SLE group, p < 0.001. All the studied comorbidities were significantly higher in SLE, the most prevalent were hypertension (53%) and chronic kidney disease (CKD, 19%) (Table 1). Men with SLE had double the prevalence of coronary artery disease (22.8% vs 12.5%), and CKD (31.2% vs 17.8%) than women, whereas obesity and depression were higher in women (11.4% vs 8.5%, and 13.6% vs 10.3%, respectively)

SLE ED had double the rate of inpatient admission (34 % vs 17%) and higher odds (OR, 95% CI) of admission than non-SLE (2.20, 2.03-2.37) even after adjustment for baseline characteristics and comorbidities. Age >50 years (ref: 18-50; 1.16, 1.07-1.25), and male sex (1.30, 1.21 – 1.4) were associated with higher odds of inpatient admission in SLE. The comorbidities with the highest odds of admission were CKD (2.91, 2.70-3.14) and obesity (2.76, 2.48-3.08). Black race (0.83, 0.74-0.93) and low income (0.86, 0.78-0.96) were associated with lower odds of admission, despite comprising a sizeable proportion of ED visits (Table 2).

Pain-related visits were among the top causes of ED visits in both SLE and non-SLE groups. Other top diagnoses for ED visits in SLE were “SLE” and infections. The major primary diagnoses for ED visits in SLE patients who got admitted were septicemia (11.01%), SLE (8.56%), and pneumonia (2.32%) (Figure1).

Conclusion: SLE ED visits had a higher comorbidity burden than non-SLE. Male sex and most of the studied comorbidities were associated with higher rates of inpatient admission from the ED. Aggressive comorbidity management may alter higher ED and inpatient use in SLE patients. Black and low income SLE patients had higher odds for treat-and-release ED visits (as also noted in prior studies), raising a possibility that these patients may rely on ED for more routine care needs as well as socioeconomic biases on the part of healthcare providers, further research is needed to better understand these differences.  

Supporting image 1

Table 1. Baseline demographic characteristics, clinical comorbidities, and outcomes of ED encounters in SLE versus non-SLE groups (% may be less than 100 due to missing values)

Supporting image 2

Table 2. Univariable and multivariable analysis of Baseline demographic characteristics and clinical comorbidities associated with inpatient admission after ED visit in patients with SLE (OR** adjusted for age, sex, race, primary payer, income quartile, and concurrent comorbidities)

Supporting image 3

Figure 1: a. Top diagnoses associated with ED visits in patients with SLE and age and sex-matched controls without SLE b. Top diagnoses associated with SLE ED visits with and without inpatient admission


Disclosures: R. Dhital, None; M. Guma, Pfizer, Novartis, Gilead, Sonoma Bio, Genentech; B. Pedersen, None; A. Pokharel, None; K. Kalunian, AbbVie/Abbott, Amgen, AstraZeneca, Aurinia, Biogen, Bristol Myers Squibb (BMS), Eli Lilly, Equillium, Genentech, Gilead, Janssen, Roche, Lupus Research Alliance, Pfizer, Sanford Consortium, Viela, Nektar.

To cite this abstract in AMA style:

Dhital R, Guma M, Pedersen B, Pokharel A, Kalunian K. Epidemiology and Outcomes of Emergency Department Visits in Systemic Lupus Erythematosus: Data from National Emergency Database Sample [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/epidemiology-and-outcomes-of-emergency-department-visits-in-systemic-lupus-erythematosus-data-from-national-emergency-database-sample/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/epidemiology-and-outcomes-of-emergency-department-visits-in-systemic-lupus-erythematosus-data-from-national-emergency-database-sample/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology